



An Investment Opportunity for Precision Nutrition for a Growing Renal Care Market

OVERVIEW

Patients undergoing dialysis experience significant protein loss while simultaneously managing strict dietary restrictions on phosphorus, potassium, sodium, and fluids. Existing nutritional supplements are often broad, non-specific protein products that may introduce additional metabolic burden. Albugenyx® was developed for this underserved population.

WHY ALBUGENYX®?

250M

people worldwide are estimated to live with kidney disease

500K

patients undergo dialysis in the United States

100K

patients begin dialysis treatment each year in the U.S.

\$5B+

projected global CKD nutritional supplement market by 2031

THE PROBLEM

Dialysis Patients Need Protein — But Conventional Protein Can Create New Challenges

Kidney failure patients lose critical proteins, including albumin, while undergoing dialysis. Traditional supplements commonly rely on large proteins, peptides, whey, dairy, soy, or plant-based sources that may require additional digestion and can introduce phosphorus, potassium, sodium, calories, or other components that renal patients must carefully manage. The market lacks a precision nutritional solution specifically designed around the metabolic needs of kidney failure patients.

THE SOLUTION

Albugenyx® is a patent-pending dietary supplement developed using a precision nutrition approach to provide targeted amino acid building blocks that support endogenous albumin biosynthesis.

Albugenyx®

- Amino acid formulation
- Targeted protein building blocks
- Designed specifically for renal care
- Formulated to support albumin biosynthesis
- Designed for enhanced amino acid availability

Conventional Protein Supplements

- Commonly contain intact proteins, peptides, or larger protein fragments
- May require greater digestion
- May contain higher amounts of phosphorus, sodium, or potassium
- Typically provide generalized rather than albumin-targeted protein nutrition

INVESTMENT OPPORTUNITY

Signature Health Labs is seeking \$500,000 in total pre-seed funding to accelerate the launch of Albugenyx®. Funds will:

- Finalize manufacturing arrangements and CDMO production
- Increase production batches
- Support introductory product launch activities
- Expand clinical data collection
- Develop post-launch sales and marketing infrastructure

BENEFITS

Recurring Revenue Potential

Daily supplementation provides a scalable, repeat-purchase business model. Millions of renal patients require ongoing nutritional support.

Strategic Partnerships

Potential strategic acquisition or commercialization partnerships with major nutrition, consumer health, renal care, and pharmaceutical organizations. Meanwhile, intellectual property protection supports long-term differentiation.

Please direct all inquiries to info@albugenyx.com

ALBUGENYX®

Precision Nutrition for a Growing Renal Care Market

A differentiated amino acid platform designed to address a critical nutritional challenge in kidney failure.

Patients undergoing dialysis experience significant protein loss while simultaneously managing strict dietary restrictions on phosphorus, potassium, sodium, and fluids. Existing nutritional supplements are often broad, non-specific protein products that may introduce additional metabolic burden.

Albugenyx® was developed specifically for this underserved population.

THE OPPORTUNITY

A Large and Growing Patient Population

850M

people worldwide are estimated to live with kidney disease

500,000+

patients undergo dialysis in the United States

100,000+

patients begin dialysis treatment each year in the U.S.

\$5B+

projected global CKD nutritional supplement market by 2031

The renal nutrition market represents a substantial recurring opportunity driven by a growing dialysis population and an unmet need for more targeted nutritional solutions.

THE PROBLEM

Dialysis Patients Need Protein – But Conventional Protein Can Create New Challenges

Kidney failure patients lose critical proteins, including albumin, while undergoing dialysis.

Traditional supplements commonly rely on large proteins, peptides, whey, dairy, soy, or plant-based sources that may require additional digestion and can introduce phosphorus, potassium, sodium, calories, or other components that renal patients must carefully manage.

The market lacks a precision nutritional solution specifically designed around the metabolic needs of kidney failure patients.

THE SOLUTION

Albugenyx®: A Renal-Specific Amino Acid Formulation

Albugenyx® is a patent-pending dietary supplement developed using a precision nutrition approach to provide targeted amino acid building blocks that support endogenous albumin biosynthesis.

Key Differentiators

Free Amino Acids

Pre-digested protein building blocks designed for efficient nutrient delivery.

Albumin-Focused Formulation

Specific amino acids selected to support albumin and protein biosynthesis.

Renal Compatibility

Designed to minimize phosphorus and excess electrolyte burden compared with many conventional protein sources.

Low Caloric Load

Provides targeted nutritional support without the caloric burden associated with many traditional renal nutrition products.

20 g Daily Format

A convenient powdered formulation designed for straightforward daily use

ALBUGENYX is associated with many traditional renal nutrition products.

20 g Daily Format

A convenient powdered formulation designed for straightforward daily use.

BUILT FOR A RECURRING REVENUE MODEL

Albugenyx® is designed as a daily-use nutritional product, creating the potential for predictable recurring demand.

Multiple Commercial Channels

Dialysis Clinics & Nephrology Practices

Hospitals, Nursing Homes & Rehabilitation Centers

Pharmacy & Retail Distribution

Direct-to-Consumer E-Commerce

The company plans to launch initially in the United States, followed by international expansion.

EARLY TRACTION

From Concept to Commercialization

2024

Product concept and formulation development began

December 2024

Provisional patent application filed

July 2025

Laboratory trial batch formulated

December 2025

Initial patient testing completed

February 2026

Non-provisional U.S. utility patent application filed

2026

Pilot production and commercial-launch preparation

Albugenyx® has progressed from formulation development into early patient testing, intellectual property protection, manufacturing preparation, and commercialization planning.

DEFENSIBLE POSITIONING

Precision Nutrition + Renal Care + Intellectual Property

Albugenyx® combines a targeted formulation strategy with a patent-pending intellectual property position.

Unlike generalized protein supplements, the formulation is designed specifically around the nutritional requirements and metabolic limitations of kidney failure patients.

This differentiated platform also provides the potential for future formulations, dosage forms, and additional nutritional applications.

THE MARKET ENTRY STRATEGY

Start Focused. Scale Strategically.

Initial commercialization will target:

Nephrology and Dialysis Networks

Building clinical awareness and professional recommendation.

Healthcare Institutions

Hospitals, skilled nursing facilities, rehabilitation centers, and other clinical nutrition environments.

Direct Consumer Access